BeOne Medicines (ONC) Other Non-Current Liabilities (2015 - 2026)

BeOne Medicines (ONC) has 12 years of Other Non-Current Liabilities data on file, last reported at $82.0 million in Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities rose 24.87% year-over-year to $82.0 million in Q1 2026; TTM through Mar 2026 was $82.0 million, a 24.87% increase from a year earlier, with the FY2025 full-year figure at $80.2 million, up 20.24% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $82.0 million, up from $80.2 million in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for ONC reached as high as $180.5 million in Q4 2022 and fell as low as $42.0 million in Q3 2023.
• Historically, Other Non-Current Liabilities has averaged $63.5 million across 5 years, with a median of $51.5 million in 2024.
• Across the five-year window, Other Non-Current Liabilities soared 232.77% in 2022 and plunged 71.85% in 2023, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $180.5 million in 2022, then plunged by 71.85% to $50.8 million in 2023, then jumped by 31.34% to $66.7 million in 2024, then increased by 20.24% to $80.2 million in 2025, then advanced by 2.13% to $82.0 million in 2026.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $82.0 million in Q1 2026, $80.2 million in Q4 2025, and $64.1 million in Q3 2025.